eResearchTechnology and Inveresk Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Services

eResearchTechnology and Inveresk Sign Agreement to Deliver
Integrated Cardiac Safety and Clinical Pharmacology Services
Fifth Clinical Research Organization Enters into Digital Cardiac Safety
Monitoring Services Agreement with eResearchTechnology 


PHILADELPHIA, April 7  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, today announced it has entered into an agreement
with Inveresk, one of the world's largest clinical research organizations.  This
alliance, the fifth for eRT, enables testing of new drug candidates in
conjunction with emerging international cardiac safety regulatory guidance and
technical standards.

Under the agreement, Inveresk will conduct clinical trials at its Phase I unit
in Edinburgh, Scotland, while eRT will perform digital collection, measurement,
interpretation, review and distribution of cardiac safety data through its
EXPeRT workflow-enabled data handling technology.  The eRT technology is the
first solution designed explicitly to meet emerging international guidance and
standards related to cardiac safety monitoring services.

"Inveresk's long operating history of providing comprehensive Phase I unit
services for over fifteen years presented a great opportunity for eRT to extend
its Thorough Phase I ECG Study partnership program to Europe," said Robert
Brown, senior vice president of outsourcing partnerships for eRT.  "The
partnershipwill help to meet increasing demand from European and North American
drug development organizations for the ability to conduct Thorough Phase I ECG
studies in Europe.  We are pleased to be announcing the Inveresk alliance and
look forward to working closely with the Inveresk team to ensure effective
execution of Thorough Phase I ECG studies."

Based in Philadelphia, Pa., eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  As a result, actual results may differ materially from any financial
outlooks stated herein.  Further information on potential factors that could
affect the company's financial results can be

found in the company's reports on Form 10-K and 10-Q filed with the Securities
and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright